Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

TGA Seeks Feedback On Updated Recall Procedure For Drugs And Devices

This article was originally published in Clinica

Executive Summary

Australia's Therapeutic Goods Administration is seeking feedback on proposed revisions to its recall procedure for drugs and medical devices.

You may also be interested in...



New Recall Procedures For Australian Therapeutic Goods Come Into Play

As of Jan. 15, sponsors of therapeutic goods in Australia must follow new recall procedures, which have been updated to ensure they are consistent with current regulatory best practice.

New Recall Procedures For Australian Therapeutic Goods Come Into Play

As of Jan. 15, sponsors of therapeutic goods in Australia must follow new recall procedures, which have been updated to ensure they are consistent with current regulatory best practice.

Yes For Shionogi But No For Lilly In Latest EMA Recommendations

The European Medicines Agency says that Shionogi’s novel antibiotic, Fetcroja, should be approved for use across Europe but that Lilly's migraine drug, Emgality, should not be authorized for the extended indication of episodic cluster headache.

Topics

UsernamePublicRestriction

Register

MT103006

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel